Sign Up
SB 289 Oregon Senate · 2025 Regular Session

Relating to prescription drugs.

Summary
] [ Requires the State Board of Pharmacy to study prescription drugs. Directs the board to submit findings to the interim committees of Legislative Assembly related to health care not later than September 15, 2026. ] [ Sunsets on January 2, 2027. ] Modifies, from quarterly to annually, the timing of the Department of Consumer and Business Services' requirement to report certain information to the Prescription Drug Affordability Board. Modifies the number of prescription drugs that may create affordability challenges that the board is directed to identify. Modifies the board's reporting requirements for the status of the generic drug market.
Bill status signed all 5 stages cleared
Introduction
Jan 2025
Committee Review
May 2025
Senate Passage
May 2025
House Passage
May 2025
Signed into Law
May 2025
Introduced Jan 13, 2025 Signed May 28, 2025
Maddy AI version diff · 2 comparisons

What changed between versions

A-Engrossed → Enrolled · 5 edits · May 28, 2025
MODERATE
This bill was finalized and enrolled for signature, with substantive additions to prescription drug reporting requirements. The enrolled version adds new reporting obligations for manufacturers, including international pricing data and documentation requirements, while maintaining the core framework of the A-Engrossed version.
Scope change
The bill's scope expanded to include new reporting requirements for international pricing comparisons and documentation support for price increase reports.
REQUIREMENT

Added requirement for manufacturers to report the 10 highest prices paid for drugs in countries other than the United States during the previous calendar year.

Added requirement for manufacturers to provide documentation supporting all price increase information reported to the department.

Modified reporting requirement to include net yearly price increases over the previous five years, not just current year increases.

Added new subsection requiring manufacturers to report detailed information about patient assistance programs, including participation numbers and total value of discounts provided.

Added requirement for manufacturers to report introductory prices and five-year price history when drugs were first approved by the FDA.

Floor votes · Senate Mar 25, 2025 · House May 15, 2025

How they voted

29–0
Passed
Total votes 29
Mar 25, 2025
D Democratic17
17 Yea
100% Yea
R Republican12
12 Yea
100% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
22
Key actions
7
Committee
4
May 28, 2025
Signed into law
Governor signed.
upper
May 20, 2025
Lower · Passed
Speaker signed.
lower
May 19, 2025
Upper · Passed
President signed.
upper
May 15, 2025
Lower · Passed
Third reading. Carried by Munoz. Passed.
lower
May 12, 2025
Lower · Passed
Recommendation: Do pass.
lower
Apr 1, 2025
Committee
Referred to Behavioral Health and Health Care.
lower
Mar 27, 2025
Introduced
First reading. Referred to Speaker's desk.
lower
Mar 25, 2025
Upper · Passed
Third reading. Carried by Patterson. Passed.
upper
Mar 19, 2025
Upper · Passed
Recommendation: Do pass with amendments. (Printed A-Eng.)
upper
Jan 17, 2025
Committee
Referred to Health Care.
upper
Jan 13, 2025
Introduced
Introduction and first reading. Referred to President's desk.
upper
0 primary · 0 co-sponsors

Sponsors

No sponsor information available.